CLINICAL EFFICACY OF THE COMBINATION OF SECOND GENERATION TYROSINE KINASE INHIBITORS AND 5-AZACITIDINE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA PATIENT IN MYELOID BLAST CRISIS

Even in the tyrosine kinase inhibitors era, the prognosis of patients with chronic myeloid leukemia in myeloid blast crisis remains to be unfavorable. Myeloid blast crisis is characterized to be refractory to cytotoxic agents and high risk of recurrence. We described the patient with chronic myeloid leukemia in myeloid blast crisis who was successfully treated by the combination of the second generation tyrosine kinase inhibitor and 5-azacytidine.